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Abstract 
We report on a patient with carboplatin-induced bilateral papilledema, as it was 
described in the 1970s for cisplatin. Loss of visual accuracy up to full blindness, often loss 
of color vision and scotomas can be seen as a result of cortical blindness, macula 
degeneration, retrobulbar neuritis and papilledema. These symptoms are mostly 
unilateral and initially mild, so that more chemotherapy is given before the diagnosis is 
made. The symptoms are usually reversible within weeks to months after cessation of the 
platinum treatment. The therapeutic strategy is stopping the platinum treatment. In 
addition the empiric use of corticosteroids is suggested. 
 
Introduction 
Mild visual impairment is common during chemotherapy. Occasionally, however, it 
can be a sign of a more serious, often unrecognized condition. We report on a patient 
with carboplatin-induced bilateral papilledema resulting in only partially reversible visual 
impairment. Despite the fact that carboplatin is widely used in the treatment of a variety 
of common tumors (including cancer of the lung, ovary, testis), this is the first report of 
carboplatin-induced papilledema following regular AUC-determined dose. Reported 
cases of papilledema after carboplatin administration include two cases after high-dose 
carboplatin (AUC12) [1], one report using carboplatin and cisplatin simultaneously [2], 
and two patients to whom carboplatin was given in a fixed standard dose (400 mg/m2) [3] 
rather than in a creatinine-clearance dependent dose (AUC). Papilledema after 
intracarotid carboplatin application [4] have also been observed. 
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Materials and Methods 
A 70-year-old woman with stage IIIc (FIGO) serous-papillary ovarian carcinoma started 
postoperative chemotherapy 5 weeks after optimal surgical debulking (TAH+BSO) in September 2005. 
Concurrent medical conditions included stable coronary heart disease, controlled arterial hypertension 
and mild urinary retention as sole sequel of a previous injury to the lower back. Baseline renal function 
was normal with a calculated creatinine clearance of 100 ml/min (Cockroft formula). Chemotherapy 
consisted of a 3-weekly intravenous administration of carboplatin (AUC 5 mg/ml × min) over 30 min 
and was well tolerated, grade 1 nausea, fatigue and grade 2 thrombocytopenia (53 × 109/l) being the only 
adverse effects. On day 8 of the 4th cycle, however, the patient was admitted because of nausea, 
constipation and acute urinary retention. Post-renal acute renal failure (calculated creatinine clearance 
40 ml/min) was completely reversible after catheterization. At this time, she first complained about 
visual impairment in her right eye (lack of focus and scattered blind spots). Other neurological signs 
were absent. 
Investigations and Differential Diagnosis 
An ophthalmologic examination revealed a bilateral papillary edema (fig. 1a, b). The optic nerve 
head was at that time more prominent in the right eye than in the left eye, and there were some 
hemorrhages within the nerve fiber layer. Visual acuity was slightly reduced in both eyes. Differential 
diagnosis of increased intracranial pressure due to meningeosis carcinomatosa or cerebral metastasis 
and anterior ischemic optic neuropathy (AION) due to anemia were discussed. An MRI of the brain 
showed no signs of intracranial pressure, leptomeningeal carcinomatosis or pathology of the optic 
nerve. 
The serum tumor marker CA-125 had normalized (from 1,541 U/ml pre-, and 114 U/ml 
postoperatively) and complete remission was confirmed by abdominal ultrasound and chest X-ray. 
Chemotherapy was therefore continued. However, after the 5th cycle the visual acuity decreased further, 
and new visual field losses in the left eye appeared. At the same time an increase of the bilateral 
papilledema was observed, particularly in the left eye. In contrast, the hemorrhages in the right eye had 
almost disappeared, and some signs of ischemia were now noted. Visual acuity had dropped to 20/100 
in the left eye and there was a left relative afferent pupillary defect. Diagnostic lumbar puncture was 
performed and intracranial pressure was measured at 10 cm H2O. Based on the normal intracranial 
pressure, the differential diagnosis of pseudotumor cerebri, a condition characterized by 
ophthalmopathy, papilledema and elevated intracranial pressure, was dismissed. Biochemical (protein, 
glucose, LDH) and cytological examination of the cerebral fluid was normal, without malignant cells. 
Tests for specific antibodies were not diagnostic: anti-CNS and anti-Yo antibodies titers were 
(marginally) elevated in the serum, but not in the cerebral fluid. Serum titers of anti-Hu, anti-Ri, anti-
Amphiphysin, anti-CV2, anti-Tr, anti-Ma-antibodies and antibodies against retinal rods, cones, Mueller 
cells as well as plexiform structures were all negative. In view of these results, an autoimmune 
syndrome – unusual in the context of ovarian cancer – seemed very unlikely. 
Diagnosis 
Based on the history, the clinical picture and the exclusion of other conditions via MRI, cerebral 
fluid examination and serum antibody-titers, the diagnosis of bilateral carboplatin-induced papilledema 
was made. 
Management and Follow-Up 
Chemotherapy was stopped after the 5th cycle and Prednisolone was initiated at a dose of 100 mg/d 
for 2 weeks, then tapered over 10 weeks. While the visual acuity in the right eye was stable, the left eye 
improved over 2 years. At this follow-up examination (2 years after cessation of chemotherapy), the 
optic nerve head showed some signs of optic atrophy with increased pallor and reduced visibility of the 
nerve fiber layer. This atrophy was more pronounced in the left eye. 
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Discussion 
In our case report, we postulate a direct toxic effect of carboplatin, as it was described 
in the 1970s for cisplatin [5–13]. In the case of cisplatin cortical blindness, macula 
degeneration, retrobulbar neuritis and papilledema were described. Clinically, a loss of 
visual accuracy up to full blindness, often loss of color vision and scotomas were seen. 
Usually these symptoms are unilateral and initially mild, so that more chemotherapy is 
given before the diagnosis is made. A correlation with renal insufficiency and arterial 
hypertension was reported [1, 2, 3]. The symptoms are usually reversible within weeks to 
months after cessation of the platinum treatment [2, 3], and the restoration of color vision 
can take up to 1 year [13]. It seems to be a cumulative toxicity, as all cases occurred after 
several cycles of chemotherapy. Furthermore, pharmacokinetic studies of cisplatin show a 
continual rise of the drug concentration in the cerebrospinal fluid with each cycle [14]. It 
is possible that the cerebrospinal fluid concentration is important for the occurrence of 
this toxicity: in one patient with blindness and a seizure equally high concentrations of 
cisplatin in the cerebrospinal fluid and the serum were measured [15]. There are no 
proven therapeutic interventions; corticosteroids are used empirically. 
The early recognition of this potentially severe side effect is paramount, since stopping 
chemotherapy before irreversible damage occurs is crucial. 
Conclusion 
Clinically relevant papilledema is a rare, but important side effect of carboplatin. It can 
occur at standard doses using creatinine-clearance dependent dose calculations (AUC) 
and it can be partly irreversible. Since carboplatin is extensively used in a variety of 
common tumors in the palliative as well as the curative setting, this potentially severe side 
effect has to be kept in mind. Early recognition followed by cessation of further 
carboplatin administration is crucial. 
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Fig. 1. a, b Bilateral papillary edema after 4th cycle. 
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